Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection. Topline safety and efficacy data are expected to be available in late third quarter of 2027.

Part 1a completed enrollment of 131 HBeAg+ participants. This represents an over enrollment prior to the planned second interim analysis; therefore, the second interim analysis for sample size re-estimation will not be performed. Part 2a also completed enrollment of 114 HBeAg- participants.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.